An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

NCT03084471 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

867

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Malignancies

Interventions

BIOLOGICAL: MEDI4736 (Durvalumab)
BIOLOGICAL: MEDI4736 (Durvalumab) + Tremelimumab

Sponsor

AstraZeneca